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Abstract
Animal models are often used to obtain a better understanding of psychiatric, neu-
rodegenerative, and neurodevelopmental disorders. Despite many years of research,
these models have not led to many novel therapies or treatments. Translating results
between species will always be difficult, and it is argued that inappropriate statistical
analyses, failure to identify the experimental unit, lack of random assignment to treat-
ment conditions, and unblinded assessment of outcomes contribute to the low rate of
translating preclinical in vivo studies into successful therapies. It is known that these
shortcomings can generate biased estimates, too many false positives and false nega-
tives, and unreproducible results. These issues have been raised repeatedly, but have
largely gone unheeded by scientists. Two recommendations are made to improve the
situation.
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Numerous animal models (lesion, transgenic, knockout, selective breeding, etc.) have
been developed for a variety of psychiatric, neurodegenerative, and neurodevelopmental
disorders. While many of these models have been helpful for understanding disease pathol-
ogy, they have been less useful for discovering potential therapies, or for predicting which
treatments will be useful in the clinic. In short, translation from in vivo animal models
(typically rodent) has been poor, despite many years of research and effort. There are many
reasons for this, including the inherent difference in biology between rodents and humans,1
particularly relating to higher cognitive functions. In addition, there is the ever-present
question of whether a particular animal model is even suitable; whether it captures the dis-
ease process of interest or faithfully mimics key aspects of the human condition. While
important, these two considerations will be put aside, and the focus will be on the design,
execution, and analysis of preclinical in vivo studies, and the role that these have on trans-
lational neuroscience.2,3,4,5,6,7,8
There are two issues that will be discussed. The first relates to litters, in particular, the
natural litter-to-litter variation (i.e. litter effects) as well as designs where an experimental
treatment is applied to whole litters rather than to the individual animals, usually because the
treatment is applied to pregnant females and therefore to all of the offspring. The second
issue relates to the quality of reported results, and how this relates to the quality of the
underlying study.
Litter effects are ubiquitous, large, and important
It is known that on many variables and across many species, monozygotic twins are more
similar than dizygotic twins, which are more similar than non-twin siblings, and which in
turn are more similar than two unrelated individuals. What has not been fully appreciated
is that all of the standard statistical methods (e.g. t-test, analysis of variance, regression,
non-parametric methods) assume that the data come from unrelated individuals. However,
rodents from the same litter are effectively dizyogtic twins; they share a large number of
genes as well as prenatal and early postnatal environments, and therefore studies need to
be designed and analysed in such a way that differences between litters do not bias or
confound the results.7,9,10,11,12,13,14,15,16,17 More specifically, this relates to the assumption
of independence of the measurements. For example, measuring blood pressure (BP) from
the left and right arm of ten randomly sampled and unrelated people only provides ten
independent measurements of BP, not twenty. This is because the left and right BP values
will be highly correlated—if the BP value measured from a person’s left arm is high, then
so will the value measured from their right arm. Similarly, animals within a litter will tend
to have values that are more similar (i.e. correlated) than animals from different litters.
This lack of independence needs to be handled appropriately in the analysis. Many animal
models are derived from highly inbred strains, and this results in reduced genotypic and
phenotypic variation. This is a different issue and unrelated to lack of independence. It
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does not mean that animals “are all the same” and that differences between litters do not
exist.
This is not a minor issue that only statistical pedants worry about, with little practical
importance for scientists. Holson and Pearce showed twenty years ago that if three treated
and three control litters are used, with two offspring per litter (total number of offspring =
12) then the false positive rate (Type I error) is 20% rather than 5% (based on actual body
weight data from their experiment).10 Furthermore, the false positive rate increases with
the number of offspring per litter: if the number of offspring per litter is 12 (total number of
offspring = 72) then the false positive rate is 80%. The error rate is also influenced by the
relative variability between and within litters, and thus will vary for each outcome. Nev-
ertheless, given that papers report the results of multiple tests (multiple outcome variables
and multiple comparisons), we can expect the literature to be rife with false positive results.
It may seem paradoxical, but in addition to too many false positives, treating the individ-
ual offspring as the experimental unit can also lead to low power (too many false negatives)
when true effects exist.10,11 This is because differences between litters is unexplained varia-
tion, and thus the “noise” in the data is increased, potentially masking true treatment effects.
In the same paper, Holson and Pearce reported that only 30% of papers in the behavioural
neurotoxicology literature correctly accounted for litter effects. A subsequent study in 1997
using forty litters found “significant litter effects. . . in varying degrees, for almost every be-
havioural, morphologic, and neuroendocrine measure; they were evident across indices of
neural, adrenal, thyroid, and immunologic functioning in adulthood”11 (and see references
therein for further studies supporting this conclusion). This paper also noted that 34% of
papers in Developmental Psychobiology correctly accounted for litter effects and only 15%
of papers in related journals. This issue has been brought up repeatedly for almost forty
years,9 but has largely been ignored by neuroscientists. One can only speculate on the
number of erroneous conclusions that have been reached, and what an incredible waste of
resources this has been.
One might argue that when many studies are conducted, including replications within
and between labs, the evidence will eventually converge to the “truth”, and therefore these
considerations are only of minor interest. Unfortunately, there is no guarantee of such con-
vergence, as the literature on the superoxide dismutase (SOD1) transgenic mouse model
of amyotrophic lateral sclerosis (ALS) demonstrates. Several treatments showed efficacy
in this model and were advanced to clinical trials, where they proved to be ineffective.18
A subsequent large-scale (>5000 mice) and properly executed study did not replicate the
previous findings.19 This study also identified litter as an important variable which affected
survival (the main outcome), and which was not taken into account in the earlier studies.
The authors also demonstrated how false positive results can arise with inappropriate exper-
imental designs and analyses. Litter effects were not the only contributing factor; a meta-
analysis of the preclinical SOD1 literature revealed that only 31% of studies reported ran-
domly assigning treatments, and even fewer reported blind assessment of outcomes.20 Lack
of randomisation and blinding are known to overstate the size of treatment effects.3,5,6,21 In
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addition, there was evidence of publication bias, where studies with positive results were
more likely to be published.20 Thus, the combination of poor experimental design, analy-
sis, and publication bias contributed to numerous incorrect decisions regarding treatment
efficacy.
When treatments are applied to whole litters
Some disease models have a distinctive experimental design feature: the treatment is ap-
plied to pregnant females (and therefore to all of the unborn animals within that female),
but the scientific interest is in the individual offspring (Figure 1). This design is com-
mon in toxicology and nutrition studies, as well as psychiatric studies which examine the
effects of maternal stress on offspring and in the valproic acid (VPA) model of autism.
Here, the “treatment” refers to the experimental manipulation that induces the disease fea-
tures, and it does not refer to a therapeutic treatment. Difficulties arise because the ex-
perimental unit (“n”; defined as the smallest physical unit that can be randomly assigned
to a treatment condition) in these cases are the pregnant dams and not the individual off-
spring.7,9,10,11,12,13,14,15,16,17 In other words, the sample size is the number of dams, and
the offspring are considered subsamples, much like the left and right kidney from a single
animal do not represent a sample size of two (n = 1, but there are two replicate measure-
ments). This may come as a surprise, and it is irrelevant that the scientific interest is in the
offspring, or that the offspring eventually become individual entities (unlike the kidneys).
Regulatory authorities have clear guidelines on the matter;22 for example, the Organisation
for Economic Co-operation and Development (OECD) has made a firm statement in their
guidelines for chemical testing: “Developmental studies using multiparous species where
multiple pups per litter are tested should include the litter in the statistical model to guard
against an inflated Type I error rates. The statistical unit of measure should be the litter and
not the pup. Experiments should be designed such that littermates are not treated as inde-
pendent observations [p. 12]”.23 There is a restriction on randomisation because only whole
litters can be assigned to the treatment or control conditions, and this needs to be reflected
in the analysis. This could be accomplished by using only one animal per litter, and then
standard methods (e.g. t-test, ANOVA, etc.) can be employed. This is not the most efficient
design, unless the excess animals can be used for other experiments. A second option is
to use more than one animal per litter, and then average the values of the animals within a
litter. These mean values are then taken forward and can be analysed using standard meth-
ods. A third option is to use multiple animals per litter, and then analysis is performed with
a nested or hierarchical model, which properly handles the structure of the data and avoids
artificially inflating the sample size (also known as pseudoreplication7,24). This method is
preferred because litter is entered as a variable in the analysis and the magnitude of the
litter effect can be quantified. When using the first two options, it is clear that to increase
the sample size and thus power, the number of litters needs to be increased. This is also true
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for the third option, but may not be so readily apparent [pp. 3–4].16
A related design issue is that greater statistical power can be achieved when littermates
are used to test a therapeutic compound versus a placebo. If the therapeutic treatment is
applied to the individual animals postnatally, then the individual animal is the experimental
unit for this comparison. This is referred to as a split-plot design and has more than one type
of experimental unit (litters for some comparisons and individual animals for others). These
studies therefore require careful planning and analysis, but scientists are rarely introduced
to these methods during the course of their training. It is not surprising therefore that the
quality of many such studies is low.
Quality of preclinical studies
Previous studies have shown that general quality of preclinical animal experiments is low,3,5,8,25,26,27
and there is increasing evidence that the quality of the design, analysis, and interpretation of
basic neuroscience research is no better. For example, Nieuwenhuis et al. recently reported
that 50% of papers misinterpret interaction effects.28 In addition, the issue of “inflated n”,
or pseudoreplication, shows up in other guises,7,29 and whole fields can misattribute cause-
and-effect relationships.30,31 There is also the concept of “researcher degrees of freedom”,
which refers to the flexibility that scientists have in choosing the main outcome variables,
statistical models, data transformations, how outliers are handled, when to stop collecting
data, and what is reported in the final paper.32 Various permutations of the above options
greatly increases the chances that at least something will be statistically significant, and this
is what tends to get reported as the sole analysis that was conducted. Given the above, it is
not surprising that the pharmaceutical industry has difficulty reproducing many published
results.33,34
We now take a closer look at some of these issues in the VPA model of autism. It is
a relatively new model and thus one would hope that the lessons of the past (e.g. SOD1
model) have been considered. Thirty-five primary research articles were identified (up to
the end of 2011) which injected pregnant dams with VPA and then analysed the effects in
the offspring. One study was excluded as key information was located in the supplementary
material, but this was not available online.35 Of the remaining studies, only four (12%)
reported randomly assigning pregnant females to the VPA or control group. Many studies
also used only a subset of the offspring from each litter, but often it was not mentioned
how the offspring were selected. It is possible that many studies did actually randomise
the dams and then randomly select a subset of the offspring, but simply did not report
it; however, randomisation is such a crucial aspect for the validity of the results that it
seems odd to omit commenting on it. Only six studies (18%) reported that the investigator
was blind to the experimental condition when collecting the data. For fourteen studies
(41%) it was not possible to determine how many dams were actually used (i.e. the sample
size), and in four studies (12%) the number of offspring used were not indicated. Ten
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studies (29%) did not indicate whether both male and female offspring were used. No
study mentioned performing a power analysis to determine a suitable sample size to detect
effects of a given magnitude—but this is probably fortuitous because only three studies
(9%) correctly identified the experimental unit! One of these used a nested design,36 the
second mentioned that litter was the experimental unit,37 and the third used one animal
from each litter.38 A list of studies can be found in the supplementary material.
A number of papers had additional statistical or experimental design issues, ranging
from trivial (e.g. reporting total degrees of freedom rather than residual degrees of freedom
for an F-statistic) to serious. These include treating individual neurons as the experimental
unit, which is distressingly common in electrophysiological studies but just as inappropriate
as treating blood pressure values taken from left and right arms as n = 2, or chopping a
single liver sample into ten pieces and thinking that measuring the expression of a gene
in each piece gives n = 10.7 If only it were so easy; clinical trials could be conducted
with tens of patients rather than hundreds or thousands. Simply take a blood sample from
twenty patients, divide it into twenty aliquots, and you now have an apparent sample size of
20× 20 = 400! Need more power? Just divide those blood samples into fifty aliquots, now
the apparent sample size is 20× 50 = 1000; error bars are minuscule, p-values are < 0.05,
and publication in a top journal looks promising. Regulatory authorities are not fooled by
such stratagems, but is seems many journal editors and peer-reviewers are.
In addition, the wording of two studies39,40 suggests that control dams did not receive
a vehicle injection, and thus any differences between groups may be partly due to the stress
of handling and injection. For some studies, the reported degrees of freedom did not cor-
respond to what would be expected based on the verbal description of the analysis, and a
number of studies did not correctly distinguish between “within-subjects” and “between-
subjects” effects.
Solutions
A number of solutions have been proposed in the past,41 but some are difficult to imple-
ment. For example, scientists could develop the skills and knowledge to design and analyse
experiments. But if this has not happened by now, it is unlikely to happen in the fore-
seeable future. An other option is to have a statistician associated with most preclinical
studies. However, there are not enough statisticians to meet this demand, and this type of
“project support” is often viewed by academic statisticians as a secondary activity. More
manuscripts could go to a statistician for peer review, but again, a lack of statisticians, and
particularly a lack of statisticians with the appropriate subject matter knowledge (just as it
is difficult to do good science without a knowledge of statistics, it is difficult to perform
a good analysis without knowledge of the science). Some have recommended registering
animal studies,42,43,44,45 but as argued elsewhere,7 this does not fit well with the goals of
preclinical discovery research.
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There are however two practical solutions which can be easily implemented. The first is
to follow the ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines
for reporting experimental results.46 More specifically, items 6 (Study design), 10 (Sample
size), 11 (Allocating animals to experimental groups), and 13 (Statistical methods) should
a be mandatory requirement for all publications involving animals and should be included
as a separate checklist that is submitted along with the manuscript, much like a conflict of
interest or a transfer of copyright form. This would be signed by the authors (either all
authors or only the primary/senior author), would go out for peer review, and would also be
published online along with the manuscript. This would have many beneficial effects. First,
it would make it easier to spot any design and analysis issues by reviewers, editors, and
other readers (who may only skim the published paper for the main findings and assume
that the design and analyses were appropriate). Currently, this can only be done by reading
through verbal descriptions located in many different parts of a manuscript and supplemen-
tary material—assuming that the relevant information is even provided. Second, and more
importantly, if scientists are required to comment on how they randomised treatment alloca-
tion, or how they ensured that assessment of outcomes was blinded, then they will conduct
their experiments accordingly if they plan on publishing in a journal that has these reporting
requirements. Similarly, if researchers are required to state what the experimental unit is
(e.g. litter, cage, individual animal, etc.), then they will be prompted to think hard about
the issue and design better experiments, or seek advice. This recommendation will not only
improve the quality of reporting, but it will also improve the quality of experiments, which
is the real benefit. In addition, many design weaknesses and analytical flaws can be spotted
at a glance, and editors and reviewers can give this the necessary weight when evaluating
manuscripts. A final benefit is that it will make quantitative reviews/meta-analyses easier,
because much of the key information will be on a single page.
The second solution is to make the provision of raw data a requirement for acceptance
of a manuscript; not “to make it available if someone asks for it”, which is the current re-
quirement for many journals, but uploaded as supplementary material or hosted by a third
party data repository. None of the VPA studies provided the data that the conclusions were
based on, making reanalysis impossible. Remarkably, of the thirty-five studies published,
only one provided the necessary information to conduct a power analysis to plan a future
study,38 and this was only because one animal per litter was used and the necessary values
could be extracted from the graphs. Datasets used in preclinical animal studies are typically
small, do not have confidentiality issues associated with them, are unlikely to be used for
further analyses by the original authors, and have no additional intellectual property issues
associated with them given that the manuscript itself has been published. It is noteworthy
that many journals require microarray data to be uploaded to a publicly available repository
(e.g. Gene Expression Omnibus or ArrayExpress), but not the corresponding behavioural
or histological data. It is perhaps not surprising that there is a relationship between study
quality and the willingness to share data.47,48,49 Publishing raw data can be taken as a sig-
nal that researchers stand behind their data and therefore their conclusions. Funding bodies
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should encourage this by requiring that data arising from the grant are made publicly avail-
able (with penalties for non-adherence). There is an inherent conflict of interest between
advancing knowledge and advancing one’s career, and it is inevitable that the latter will oc-
casionally come at the expense of the former. Even though most researchers are honest and
well-intentioned, the appropriate structures should be put in place to ensure that appropriate
design and analyses were used, and to make it easy to verify claims or to reanalyse data.
Currently, it is often difficult to establish the former and almost impossible to perform the
latter. Moreover, it is clear that appropriate designs and analyses are often not used, making
it difficult to give the benefit of the doubt to those studies with incomplete reporting of how
experiments were conducted and data analysed.
While it is difficult to quantify the extent to which poor statistical practices hinder trans-
lational (as well as fundamental) research, it is clear that a large inflation of false positive
and false negative rates will only slow progress down. In addition, because of publication
bias and researcher degrees of freedom, it is possible for a field to converge to the wrong an-
swer. Experimental design and statistical issues are, in principle, fixable. Improving these
will allow scientists to focus on creating and assessing the suitability of disease models and
the efficacy of therapeutic interventions, which is challenging enough.
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Treatment Control
Pregnant females
 randomised to
treatment or control
condition (n = 6)
Within-litter
variation
(from 3 animals
per litter)
Between-litter variation
Between-group variation
Between-litter variation
Y
Y
Y
Y
Average of
 animals within litters 
 gives 6 values to be 
used for analysis
Figure 1: Defining the experimental unit. Pregnant females are the experimental units
because they are randomised to the treatment (e.g. valproic acid) or control conditions,
and therefore n = 6 in this example. The three offspring within a litter will often be
more similar than offspring from different litters
(
Between−litter variation
Within−litter variation > 1
)
, and multiple
offspring within a litter can be thought of as subsamples or “technical replicates”, even
though these are the scientific unit of interest. Only the mean of the within-litter values are
important when comparing treated and control groups. Using all of the offspring without
averaging will result in an inflated sample size (pseudoreplication) when using standard
analyses. Instead of averaging, one could randomly select only one animal from each litter,
or use a nested or hierarchical model to appropriately partition the different sources of
variation. The only way to increase sample size, and thus power, is to increase the number
of litters used.
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